Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAHTALYST trial of crinecerfont in adults with classic congenital adrenal hyperplasia
NL-OMON52563Phase 3Withdrawn
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of crinecerfont in classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (21-OHD) (3 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Percent change from baseline in glucocorticoid daily dose at Week 24. Planned start Nov 2020; status: withdrawn.
02
Drugs
crinecerfont
03
Conditions
classic congenital adrenal hyperplasia21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on NL-OMON52563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52563.